Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]

Dr. Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LALuca Arecco
Luca Arecco
T[Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]
Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]
VMVALENTINO MARTELLI
VALENTINO MARTELLI
ABAndrea Boutros
Andrea Boutros
MLmaria maddalena latocca
maria maddalena latocca
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
A significant number of women receive a cancer diagnosis before their age of natural menopause. Among these patients, the most frequent neoplasms are breast cancer, gynecological, and hematological malignancies. Premature ovarian insufficiency and infertility are among the most feared short- to long-term consequences of anticancer treatments in premenopausal patients. Both patient- and treatment-related characteristics are key factors in influencing the risk of gonadotoxicity with the use of chemotherapy. The cryopreservation of oocytes/embryos is a standard strategy for fertility preservations offered to young women interested in future family planning, but it does not allow gonadal function protection during chemotherapy. Ovarian suppression with gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is now recommended as an option to reduce the risk of gonadotoxicity in order to avoid the negative consequences of premature ovarian insufficiency in premenopausal women receiving cytotoxic therapy, including those not interested in fertility preservation. This review summarizes the risk of treatment-induced gonadotoxicity in premenopausal patients and the evidence available on the protective role of administering GnRHa during chemotherapy to preserve ovarian function.

Verified
Journal Article
Open access
PDF file
AGAtzori Giulia
Atzori Giulia
MGMarco Gipponi
Marco Gipponi
CCChiara Cornacchia
Chiara Cornacchia
RDRaquel Diaz
Raquel Diaz
MSMarco Sparavigna
Marco Sparavigna
PFPiero Fregatti
Piero Fregatti
Background/Aim: Patients with Stage I-II breast cancer undergoing breast-conserving surgery after neoadjuvant chemotherapy (BCS-NAC) were retrospectively assessed in order to evaluate the extent of a safe excision margin. Materials and Methods: Between 2003 and 2020, 151 patients underwent risk-adapted BCS-NAC; margin involvement was always assessed at definitive histology. Patients with complete pathological response (pCR) were classified as the RX group, whereas those with residual disease and negative margins were stratified as R0 < 1 mm (margin < 1 mm) and R0 > 1 mm (margin > 1 mm). Results: Totals of 29 (19.2%), 64 (42.4%), and 58 patients (38.4%) were included in the R0 < 1 mm, R0 > 1 mm, and RX groups, respectively, and 2 patients with margin involvement had a mastectomy. Ten instances of local recurrence (6.6%) occurred, with no statistically significant difference in local recurrence-free survival (LRFS) between the three groups. A statistically significant advantage of disease-free survival (p = 0.002) and overall survival (p = 0.010) was observed in patients with pCR. Conclusions: BCS-NAC was increased, especially in HER-2-positive and triple-negative tumors; risk-adapted BCS should be preferably pursued to highlight the cosmetic benefit of NAC. The similar rate of LRFS in the three groups of patients suggests a shift toward the “no ink on tumor” paradigm for patients undergoing BCS-NAC.

29 September 2024 in Onco
Verified
Journal Article
Open access
PDF file
RGRiccardo Gili
Riccardo Gili
SCSimone Caprioli
Simone Caprioli
PCPaola Lovino Camerino
Paola Lovino Camerino
GSGianluca Sacco
Gianluca Sacco
T[Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]
Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]
GCGiuseppe Cittadini
Giuseppe Cittadini
Background: For patients with head and neck squamous cell carcinoma (HNSCC), after a single or multi-modality treatment, a specific follow-up strategy is needed, but there is no agreement between the main international societies on the proper methods and timing of follow-up. Methods: We performed a descriptive review to evaluate the available data and compare the main guidelines, giving some practical guidance to perform effective personalized follow-up strategies. Results and Conclusions: While clinical and endoscopic follow-up alone seems to be appropriate for early-stage HNSCCs, the addition of close radiologic follow-up in locally advanced HNSCCs is still debated, as there are no data indicating that an earlier detection of recurrence correlates with increased survival, while it is mandatory in the first three-six months to define the response to treatment. For patients who have undergone conservative surgery or have major pathological risk factors, the incidence of locoregional recurrence is higher, and locoregional radiologic follow-up (magnetic resonance imaging is preferred to computed tomography) should be considered. Positron emission tomography may be useful in cases of suspected locoregional persistence of disease, differentiating it from post-irradiation outcomes. Distant radiological follow-up can be considered in the detection of the second primary in cases of specific risk factors and for virus-related tumors. For the latter, the use of circulating DNA should always be considered. A brain scan is not recommended without specific symptoms. For all patients who do not fall into the above categories, clinical and endoscopic follow-up should be proposed, reserving radiological investigations only at the onset of symptoms.

6 January 2026 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
T[Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]
Tommaso Ruelle Ospedale San Martino di Genova - [ST0449IT]
TGT. Grinda
T. Grinda
Lucia Del MastroLucia Del Mastro
Lucia Del Mastro
MLM. Lacroix-Triki
M. Lacroix-Triki
BPB. Pistilli
B. Pistilli
GGG. Gessain
G. Gessain
The global increase in breast cancer incidence is determining substantial augment of pathologists’ workload. Digital pathology (DP), which consists of digitizing haematoxylin–eosin (H&E)-stained slides into whole-slide images, enables new workflows and horizons. The integration of artificial intelligence (AI) with DP led to the emergence of computational pathology (CP), which has the potential of offering valuable diagnostic, prognostic and predictive tools. The aim of this narrative review is to provide an overview of the state of the art in this rapidly evolving field. Several AI tools demonstrated enhanced performances as compared with visual evaluation of pathologists, such as identification of invasive breast cancers, sentinel lymph node metastasis, histological grading, Ki-67, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2) and programmed death-ligand 1 (PD-L1) quantification. Due to this, most of them are currently authorized in the European market. Beyond diagnosis, CP has shown strong potential in predicting, from a simple H&E digital slide, treatment response (e.g. neoadjuvant chemotherapy, anti-HER2 therapy and endocrine therapy), immunohistochemistry status (ER, PR, HER2, PD-L1), molecular alterations (e.g. BRCA1/2 and homologous recombination deficiency status), genomic signatures (e.g. Oncotype DX) and ultimately the patient’s risk of recurrence. Despite challenges such as high validation costs, initial economic investments and potential AI biases, CP holds great promise. Continued effort to address these barriers and improve AI reliability are crucial. Emerging AI tools, including agent-driven systems, point towards the potential integration of CP into routine clinical workflow practice, even though clinical validation has not yet been established.